276.2 𩺠åèç
276.2.1 é«é »èé»
276.2.1.1 Definitions
- ACC/AHA 2017: ⥠130/80
- ESC 2023: ⥠140/90
- ABPM diagnostic: 24h ⥠130/80, day ⥠135/85, night ⥠120/70
- HBPM diagnostic: ⥠135/85
276.2.1.2 Secondary HTN â When to Test (Red Flags)
- Young (< 30) or new severe HTN
- Resistant HTN (3 drugs incl diuretic at max dose)
- Hypokalemia without diuretic
- Episodic
- Target organ damage out of proportion
276.2.1.3 Top Secondary Causes
- Primary aldosteronism (5-10%) â aldosterone/renin ratio
- OSA (30-40% of HTN; treat with CPAP)
- Renal artery stenosis (atherosclerotic or FMD)
- Pheochromocytoma (24h urine or plasma metanephrines)
- CKD (eGFR + UA)
- Cushingâs (cortisol screening)
- Hyperthyroidism
- Coarctation (arm-leg BP gradient)
276.2.1.4 Drug-Induced HTN
- NSAIDs, OCPs, steroids, decongestants, EPO, calcineurin inh, cocaine, alcohol
276.2.1.5 Key Trials
- SPRINT (2015): intensive (< 120) vs standard (< 140) â â MACE, â mortality in non-DM
- STEP (2021): similar benefit in elderly Chinese (60-80)
- PATHWAY-2 (2015): spironolactone best add-on for resistant HTN
- SYMPLICITY HTN-3 (2014): renal denervation initially negative, RADIANCE-HTN + SPYRAL-HTN-OFF MED (2018-2020) showed BP effect with new technology